305 ILCS 5/5-5.25a: Coverage for seizure detection devices.

(a) As used in this Section, "seizure detection device" means a monitoring device cleared by the United States Food and Drug Administration, and any related technology, application, service, or subscription supporting the prescribed use of the device, that provides the following:

(1) individual monitoring and alert services relating to seizure activity;

(2) detection or prediction of seizure activity and transmission of notification of the seizure activity to the individual or a caregiver for appropriate medical response; or

(3) collection of data of the seizure activity of the individual that can be used by a health care provider to diagnose or appropriately treat a health care condition that causes the seizure activity.

(b) All seizure detection devices covered under this Section shall be approved for use by individuals, provided that the device has been prescribed and determined to be medically necessary. The choice of device shall be made based upon the individual's circumstances and medical needs in consultation with the individual's medical provider.

(c) Any individual who has been prescribed a seizure detection device shall not be required to obtain prior authorization for coverage for a seizure detection device, and coverage shall be continuous once the seizure detection device is prescribed.

(d) Notwithstanding any other provision of this Section, commencing July 1, 2027, all seizure detection devices cleared by the United States Food and Drug Administration shall be covered under the medical assistance program for persons who have been prescribed a seizure detection device and who are otherwise eligible for assistance under this Article.

(e) The Department shall not adopt rules or classification policies that would limit the ability of individuals covered by this Section to obtain seizure detection devices.